- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
EC approves Helsinn’s Akynzeo for prevention of chemotherapy-induced nausea and vomiting
3 June 2015 • Author: Victoria White
The European Commission (EC) has approved Helsinn’s Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin‑based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.
The decision followed the Positive Opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) and is applicable to all 28 European Union member countries, as well as Iceland, Liechtenstein and Norway.
Akynzeo is a new oral fixed dose combination of a highly-selective NK1 receptor antagonist, and palonosetron, a 5-HT3receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV).
CINV is one of the most common side effects of chemotherapy. Its management has been refined over the past several decades, but despite the existence of effective treatments and clear antiemetic guidelines, many patients still suffer from CINV, particularly during the delayed phase after chemotherapy. Studies show that patients often receive antiemetic drug regimens that are inconsistent with CINV treatment guidelines, which call for multiple-pathway targeted antiemetic prophylaxis.
Akynzeo provides a combination of two antiemetics in a single oral capsule
Akynzeo provides a combination of two antiemetics in a single oral capsule. A scheme of an NK1 receptor antagonist, a 5-HT3 receptor antagonist and dexamethasone meets the guidelines’ recommendation for optimal antiemetic therapy following highly emetogenic and anthracycline cyclophosphamide based chemotherapy.
Riccardo Braglia, Helsinn Group Chief Executive Officer, commented: “Helsinn is proud to announce the EU approval of Akynzeo by the EC, which will allow us to provide patients living with cancer across Europe with an improved option for CINV protection. Akynzeo will play a significant role in preventing nausea and vomiting in both the acute and delayed phases following chemotherapy treatment, which could lead to more treatment options for the patient.”
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics